复方丹参滴丸联合曲美他嗪治疗冠心病伴心绞痛的临床疗效

摘要

目的：探究复方丹参滴丸联合曲美他嗪治疗冠心病伴心绞痛的临床疗效。方法选取定陶县人民医院2013年10月—2015年6月收治的冠心病伴心绞痛患者136例，按照随机数字表法分为观察组和对照组，每组68例。两组患者均给予常规治疗，对照组患者在此基础上联合曲美他嗪口服治疗，观察组患者在对照组基础上联合复方丹参滴丸口服治疗；两组患者均治疗14 d。比较两组患者心绞痛症状临床疗效、心电图临床疗效及不良反应发生情况，治疗前后血脂指标〔总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（ LDL-C）〕、血液流变学指标〔全血黏度（WBV）、血浆黏度（pV）〕及纤维蛋白原（FIB）水平。结果观察组患者心绞痛症状临床疗效、心电图临床疗效均优于对照组（ u 值分别为2.843、2.517，P <0.05）。两组患者治疗前 TC、TG、HDL-C、LDL-C 水平比较，差异无统计学意义（ P >0.05）；观察组患者治疗后 TC、TG、LDL-C 水平低于对照组， HDL-C 水平高于对照组（P <0.05）。两组患者治疗前 WBV、pV 及 FIB 水平比较，差异无统计学意义（P >0.05）；观察组患者治疗后 WBV、pV 及 FIB 水平均低于对照组（P <0.05）。两组患者治疗过程中均未出现严重药物相关不良反应。结论复方丹参滴丸联合曲美他嗪治疗冠心病伴心绞痛的临床疗效确切，能有效改善患者的血脂代谢及血液流变学指标，且无明显不良反应。%Objective To investigate the clinical effect of compound danshen dripping pills combined with trimetazidine on angina pectoris in patients with coronary heart disease. Methods A total of 136 coronary heart disease patients complicated with angina pectoris were selected in the people′s Hospital of Dingtao County from October 2013 to June 2015,and they were divided into control group and observation group according to random number table,each of 68 cases. Based on conventional treatment,patients of control group were given extra trimetazidine,while patients of observation group were given compound danshen dripping pills combined with trimetazidine,both groups continuously treated for 14 days. Curative effect of pectoris symptoms and electrocardiogram,incidence of adverse reactions,blood lipids index(including TC,TG,HDL-C and LDL-C),hemodynamic index( including whole blood viscosity,plasma viscosity) and fibrinogen before and after treatment were compared between the two groups. Results Curative effect of pectoris symptoms(u = 2. 843) and electrocardiogram(u= 2. 517)of observation group were both statistically significantly better than those of control group(P < 0. 05). No statistically significant differences of TC,TG,HDL-C or LDL-C was found between the two groups before treatment( P > 0. 05);after treatment,TC,TG and LDL-C of observation group were statistically significantly lower than those of control group,while HDL-C of observation group was statistically significantly higher than that of control group(P < 0. 05). No statistically significant differences of WBV,pV or FIB was found between the two groups before treatment(P > 0. 05),while WBV,pV and FIB of observation group were statistically significantly lower than those of control group after treatment(P < 0. 05). No one of the two groups occurred any serious drug related adverse reactions during treatment. Conclusion Compound danshen dripping pills combined with trimetazidine has certain clinical effect in treating angina pectoris in patients with coronary heart disease,can effectively improve the blood lipid metabolism and hemodynamic index,has less adverse reactions.